fashion -WSS

fashion

author：knowledge 2025-10-01 23:07:14 - browse：727

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Generative AI mines health records to identify patients’ social needs

hotspot

WSS

Designating disabled people as health disparity population is crucial

Doulas covered by Medicaid under New York's new plan

New Medicare drug pricing powers could soon be upended in court

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Britney Spears to release memoir, 'The Woman In Me,' later this year

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

fashion

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Tori Bowie and the unacceptable rates of Black maternal death

Superbugs, antibiotic resistance get scrutiny in congress

What does generative AI mean for health care? We asked experts

GSK to buy asthma

At least 13 dead in Texas as scorching temps continue

Companies helping big Covid

The high cost of giving birth even with insurance

As JPM 2024 winds down, some health tech firms project optimism

focus

JPM 2024: Nvidia claims we're in biological revolution. Are we?

GSK to buy asthma

EU fines Illumina $475 million over Grail acquisition

Vermont grapples with historic flooding as more rainstorms head for Northeast

How I ended up pumping milk in a bathroom stall at JPM 2024

New Medicare drug pricing powers could soon be upended in court

entertainment

hotspot

focus

focus